A Phase 3 interventional study of Amivantamab and Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 232 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 33rd largest by enrollment of the 223 interventional ones that give a count, is one of 13 that started in 2020, is one of 44 in phase 3, reaches primary completion later than 1 of the 31 other live ones, and was the 195th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 47 · Phase 4 8
First in 2001; this study’s year is marked. 13 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 308 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 64 across the 223 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 227 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson: 7 open now, 18 under way, 4 of them phase 3. Of 15 finished, 7 (47%) have results posted.
Among the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 3, reaches primary completion later than 0 of the 17 other live ones, and was the 18th registered.
Johnson & Johnson’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2012.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Johnson & Johnson’s 36 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pemetrexed 500 milligram per meter square (mg/m\^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.
Drug: Amivantamab · Drug: Pemetrexed · Drug: Carboplatin
Participants will receive pemetrexed 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.
Drug: Carboplatin · Drug: Pemetrexed
Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
Also known as: JNJ-61186372
Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.
Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).
Time frame: From randomization to either disease progression or death whichever occurs first (up to 29 months)
Objective Response Rate (ORR)
Time frame: Up to 5 years 3 months
Duration of Response (DoR)
Time frame: Up to 5 years 3 months
Overall Survival (OS)
Time frame: Up to 5 years 3 months
Time to Subsequent Therapy (TST)
Time frame: Up to 5 years 3 months
Progression-Free Survival After First Subsequent Therapy (PFS2)
Time frame: Up to 5 years 3 months
Time to Symptomatic Progression (TTSP)
Time frame: Up to 5 years 3 months
Number of Participants Treatment-emergent Adverse Events (TEAEs)
Time frame: From Day 1 to 5 years 2 months
Number of Participants TEAEs With Severity
Time frame: From Day 1 to 5 years 2 months
Number of Participants With Clinical Laboratory Abnormalities
Time frame: Up to 5 years 3 months
Number of Participants With Vital Signs Abnormalities
Time frame: Up to 5 years 3 months
Number of Participants With Physical Examination Abnormalities
Time frame: Up to 5 years 3 months
Serum Concentration of Amivantamab
Time frame: Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1)
Number of Participants With Anti-Amivantamab Antibodies
Time frame: Day 1 (Cycles 1, 2, 3, 5, 7, 9, 11, 13), Day 2 (Cycle 1)
Change From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Time frame: From baseline to 5 years 3 months
Change From Baseline in Patient Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF)
Time frame: From baseline to 5 years 3 months
| Milestone | Arm B: Chemotherapy Alone | Arm A: Amivantamab + Chemotherapy |
|---|---|---|
| Started | 155 | 153 |
| Treated | 155 | 151 |
| Completed | 42 | 28 |
| Not completed | 113 | 125 |
| Withdrew: Withdrawal by subject | 5 | 9 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Ongoing | 106 | 115 |
PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).
| Months | Arm B: Chemotherapy Alone | Arm A: Amivantamab + Chemotherapy |
|---|---|---|
| Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) | 6.70 (5.59 to 7.33) | 11.37 (9.79 to 13.70) |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From baseline (Day 1 of Cycle 1) up to 29 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm B: Chemotherapy Alone | 42/155 (27.1%) | 48/155 (31%) | 149/155 (96.1%) |
| Arm A: Amivantamab + Chemotherapy | 28/151 (18.5%) | 56/151 (37.1%) | 151/151 (100%) |
| Event | Arm B: Chemotherapy Alone | Arm A: Amivantamab + Chemotherapy |
|---|---|---|
| PneumoniaInfections and infestations | 4/155 | 6/151 |
| AnaemiaBlood and lymphatic system disorders | 6/155 | 1/151 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/155 | 1/151 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 5/155 | 1/151 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/155 | 3/151 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/155 | 4/151 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 4/155 | 4/151 |
| Covid-19Infections and infestations | 1/155 | 3/151 |
| VomitingGastrointestinal disorders | 1/155 | 3/151 |
| HypokalaemiaMetabolism and nutrition disorders | 1/155 | 3/151 |
| Event | Arm B: Chemotherapy Alone | Arm A: Amivantamab + Chemotherapy |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 70/155 | 88/151 |
| ParonychiaInfections and infestations | 0/155 | 85/151 |
| AnaemiaBlood and lymphatic system disorders | 84/155 | 76/151 |
| RashSkin and subcutaneous tissue disorders | 12/155 | 81/151 |
| NauseaGastrointestinal disorders | 65/155 | 55/151 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 2/155 | 63/151 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 15/155 | 62/151 |
| ConstipationGastrointestinal disorders | 47/155 | 60/151 |
| LeukopeniaBlood and lymphatic system disorders | 50/155 | 56/151 |
| ThrombocytopeniaBlood and lymphatic system disorders | 46/155 | 55/151 |
| Age, Continuous(years) | Arm B: Chemotherapy Alone | Arm A: Amivantamab + Chemotherapy | Total |
|---|---|---|---|
| Mean | 60 ± 12.01 | 59.3 ± 11.92 | 59.6 ± 11.95 |
| Sex: Female, Male(Participants) | Arm B: Chemotherapy Alone | Arm A: Amivantamab + Chemotherapy | Total |
|---|---|---|---|
| Female | 93 | 85 | 178 |
| Male | 62 | 68 | 130 |
| Ethnicity (NIH/OMB)(Participants) | Arm B: Chemotherapy Alone | Arm A: Amivantamab + Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 13 | 22 |
| Not Hispanic or Latino | 145 | 137 | 282 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Race (NIH/OMB)(Participants) | Arm B: Chemotherapy Alone | Arm A: Amivantamab + Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 89 | 97 | 186 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 60 | 49 | 109 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Region of Enrollment(Participants) | Arm B: Chemotherapy Alone | Arm A: Amivantamab + Chemotherapy | Total |
|---|---|---|---|
| AUSTRALIA | 4 | 2 | 6 |
| BELGIUM | 1 | 2 | 3 |
| BRAZIL | 5 | 6 | 11 |
| CANADA | 3 | 5 | 8 |
| CHINA | 48 | 39 | 87 |
| FRANCE | 4 | 3 | 7 |
| GERMANY | 2 | 0 | 2 |
| HUNGARY | 0 | 1 | 1 |
| INDIA | 6 | 5 | 11 |
| ISRAEL | 2 | 1 | 3 |
| ITALY | 5 | 7 | 12 |
| JAPAN | 15 | 19 | 34 |
| MALAYSIA | 1 | 10 | 11 |
| MEXICO | 2 | 1 | 3 |
| POLAND | 2 | 4 | 6 |
| PORTUGAL | 3 | 1 | 4 |
| RUSSIAN FEDERATION | 3 | 0 | 3 |
| SOUTH KOREA | 10 | 13 | 23 |
| SPAIN | 13 | 16 | 29 |
| TAIWAN | 5 | 4 | 9 |
| THAILAND | 0 | 2 | 2 |
| TURKEY | 10 | 3 | 13 |
| UNITED KINGDOM | 3 | 1 | 4 |
| UNITED STATES | 8 | 8 | 16 |
Showing the first 100 of 232 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Oct 2020 to primary completion in May 2023, 30 months.
Results were first posted in May 2024, 1 year after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 30 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Dec 2027, on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Carboplatin
Carcinoma, Non-Small-Cell Lung →
Janssen Research & Development, LLC →